Pre-Open Movers 07/20: (SLS) (RWLK) (PTCT) Higher; (SKX) (ZYNE) (FTD) Lower (more...)
- S&P 500, Nasdaq hit record closing peaks on eve of Fed meeting
- Oil steadies after hitting 2-yr high as demand hopes face supply growth
- Bitcoin (BTC) Price Pops 10% as Tesla's Musk Signals Another U-Turn on Bitcoin Payments
- Lordstown Motors (RIDE): CEO and CFO Resign, Presents Results of Investigation Of Hindenburg Research Report
- Paul Tudor Jones is 'Probably' Buying Commodities, Crypto, Gold if Fed Continues to Ignore Inflation Concerns, Endorses Bitcoin (BTC) as a Portfolio Diversifier
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Pre-Open Stock Movers
Skechers USA (NYSE: SKX) 27.7% LOWER; reported Q2 EPS of $0.29, $0.12 worse than the analyst estimate of $0.41. Revenue for the quarter came in at $1.13 billion versus the consensus estimate of $1.13 billion.
SELLAS Life Sciences Group Inc. (NASDAQ: SLS) 23.3% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Companys lead asset, galinpepimut-S (GPS), for the treatment of multiple myeloma (MM). GPS is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types.
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) 23.2% LOWER; announced the pricing of an underwritten public offering of 4,062,500 shares of its common stock at a price of $8.00 per share.
ReWalk Robotics, Ltd. (Nasdaq: RWLK) 17.8% HIGHER; announced that the U.S. Department of Veterans Affairs has issued a revision to its national policy on exoskeleton medical device training and procurement for qualifying Veterans with spinal cord injury (SCI). The updated policy includes further guidance on the evaluation process and expands access to training program locations among the VA network and private rehabilitation centers through the VA's Veterans Choice Program.
FTD Companies, Inc. (Nasdaq: FTD) 17% LOWER; announced that its Board of Directors has initiated a review of strategic alternatives focused on maximizing stockholder value. The strategic alternatives expected to be considered include, but are not limited to, a sale or merger of the Company, FTD continuing to pursue value-enhancing initiatives as a standalone company, a capital structure optimization that may involve potential financings, or the sale or other disposition of certain of the Companys businesses or assets. FTD has retained Moelis & Company LLC as financial advisor to assist with its strategic alternatives review. The FTD Board of Directors also announced that it has appointed Scott D. Levin, currently FTDs Executive Vice President, General Counsel and Secretary, as interim President and Chief Executive Officer. Mr. Levin succeeds John C. Walden, who has stepped down from these positions and from FTD's board of directors, effective immediately.
PTC Therapeutics, Inc. (NASDAQ: PTCT) 7.8% HIGHER; entered into an agreement to acquire Agilis Biotherapeutics, Inc., a biotechnology company advancing an innovative gene therapy platform for rare monogenic diseases that affect the central nervous system (CNS). The transaction was approved by the Boards of both companies.
Cleveland-Cliffs (NYSE: CLF) 7.5% HIGHER; reported Q2 EPS of $0.76, $0.27 better than the analyst estimate of $0.49. Revenue for the quarter came in at $714 million versus the consensus estimate of $641.77 million.
Celanese Corp. (NYSE: CE) 5.9% HIGHER; reported Q2 EPS of $2.90, $0.45 better than the analyst estimate of $2.45. Revenue for the quarter came in at $1.84 billion versus the consensus estimate of $1.81 billion. Celanese Corp. sees FY2018 EPS of $10.50-$10.75, versus the consensus of $9.64.
Galmed Pharmaceuticals (NASDAQ: GLMD) 4.9% HIGHER; Raymond James initiates coverage with a Outperform rating.
Intuitive Surgical (NASDAQ: ISRG) 4.2% HIGHER; reported Q2 EPS of $2.76, $0.26 better than the analyst estimate of $2.50. Revenue for the quarter came in at $909 million versus the consensus estimate of $877.56 million.
Skyworks Solutions (NASDAQ: SWKS) 3.5% HIGHER; reported Q3 EPS of $1.64, $0.04 better than the analyst estimate of $1.60. Revenue for the quarter came in at $894.3 million versus the consensus estimate of $889.05 million.
Stanley Black & Decker (NYSE: SWK) 2.9% HIGHER; reported Q2 EPS of $2.57, $0.53 better than the analyst estimate of $2.04. Revenue for the quarter came in at $3.6 billion versus the consensus estimate of $3.5 billion.
Viking Therapeutic (NASDAQ: VKTX) 2.7% HIGHER; SunTrust Robinson Humphrey initiates coverage on with a Buy rating and a price target of $14.00.
Platform Specialty Products Corporation (NYSE: PAH) 2.2% HIGHER; announced today that it has signed a definitive agreement to sell its Agricultural Solutions business, which consists of Arysta LifeScience Inc. and its subsidiaries (collectively, Arysta), to UPL Corporation Ltd. (UPL) for $4.2 billion in cash, subject to customary closing conditions, adjustments and regulatory approvals.
Capital One Financial (NYSE: COF) 2% LOWER; reported Q2 EPS of $3.22, $0.59 better than the analyst estimate of $2.63. Revenue for the quarter came in at $7.2 billion versus the consensus estimate of $6.95 billion.
Manhattan Bridge Capital, Inc. (NASDAQ: LOAN) 1.4% LOWER; announced today that it is proposing to offer its common shares in an underwritten public offering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertical Aerospace to Float on NYSE After a $2.2 Billion SPAC Merger, American Airlines, Rolls-Royce and Microsoft's VC Fund All Invest and 1,000 Pre-Orders Announced
- Vroom (VRM) Announces Proposed Convertible Senior Notes Offering
- Pre-Open Stock Movers 06/14: (RAPT) (CRSR) (RIOT) Higher; (ATXI) (RIDE) (RACE) Lower (more...)
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesRaymond James, SunTrust Robinson Humphrey, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!